Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy.


Journal

FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716

Informations de publication

Date de publication:
02 2021
Historique:
received: 15 05 2020
revised: 02 12 2020
accepted: 24 12 2020
pubmed: 16 1 2021
medline: 15 12 2021
entrez: 15 1 2021
Statut: ppublish

Résumé

Xanthine oxidoreductase (XOR) is a critical enzyme in purine metabolism and uric acid production, and its levels are reported to increase during stress, thereby promoting organ damage. Herein, we investigated the activity of XOR in a mouse model of aristolochic acid I (AA)-induced nephropathy, a type of nephrotoxic chronic kidney disease (CKD). A persistent decrease in renal function was observed in mice up to 4 weeks after 4 weeks of AA (2.5 mg kg

Identifiants

pubmed: 33448693
doi: 10.1002/2211-5463.13083
pmc: PMC7876505
doi:

Substances chimiques

Aristolochic Acids 0
aristolochic acid I 94218WFP5T
Xanthine Dehydrogenase EC 1.17.1.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

507-518

Informations de copyright

© 2021 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

Sci Rep. 2017 Apr 28;7(1):1266
pubmed: 28455534
Biochim Biophys Acta. 1998 Jul 23;1381(2):191-202
pubmed: 9685639
FASEB J. 1995 Aug;9(11):995-1003
pubmed: 7649415
Nat Commun. 2015 Mar 24;6:6555
pubmed: 25800347
Am J Kidney Dis. 2019 Mar;73(3):332-343
pubmed: 30454885
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:189-197
pubmed: 26673227
Hypertension. 2018 Jan;71(1):78-86
pubmed: 29203632
JCI Insight. 2017 Nov 16;2(22):
pubmed: 29202460
J Leukoc Biol. 2019 Feb;105(2):377-399
pubmed: 30589456
J Am Heart Assoc. 2015 Mar 19;4(3):e001594
pubmed: 25792129
Transl Res. 2015 Apr;165(4):512-30
pubmed: 25176603
Q Rev Biophys. 1988 Aug;21(3):299-329
pubmed: 3065813
Hypertension. 2009 Oct;54(4):868-76
pubmed: 19667249
Sci Rep. 2017 Oct 12;7(1):13086
pubmed: 29026167
J Clin Hypertens (Greenwich). 2019 Jul;21(7):966-974
pubmed: 31169986
Kidney Int. 2006 Feb;69(3):488-94
pubmed: 16514431
J Am Soc Nephrol. 2014 May;25(5):1013-27
pubmed: 24357671
Prog Exp Tumor Res. 2005;38:89-114
pubmed: 15746531
Pediatr Res. 1988 Feb;23(2):143-50
pubmed: 3281119
N Engl J Med. 1985 Jan 17;312(3):159-63
pubmed: 2981404
J Am Soc Nephrol. 1999 Oct;10(10):2146-57
pubmed: 10505691
Hypertension. 2001 Nov;38(5):1101-6
pubmed: 11711505
J Biochem. 1994 Jul;116(1):1-6
pubmed: 7798166
Kidney Int. 2014 Sep;86(3):570-81
pubmed: 24694992
Int J Cardiol. 2016 Jun 15;213:28-32
pubmed: 26318389
Mediators Inflamm. 2016;2016:8603164
pubmed: 28070145
Nephron Extra. 2013 Jan 11;3(1):12-29
pubmed: 23610565
Am J Physiol. 1997 Feb;272(2 Pt 1):G281-8
pubmed: 9124352
Hypertension. 2013 May;61(5):948-51
pubmed: 23460277
Kidney Int. 2012 Nov;82(10):1105-13
pubmed: 22854641
Hypertension. 2013 Jun;61(6):1203-10
pubmed: 23529167
Nephrol Dial Transplant. 2007 Jun;22(6):1512-7
pubmed: 17405785
Monatsh Chem. 2017;148(11):1971-1981
pubmed: 29104318
Mol Immunol. 2018 Nov;103:115-124
pubmed: 30248487
Am J Pathol. 2008 Sep;173(3):631-42
pubmed: 18688035
Arch Toxicol. 2016 Nov;90(11):2595-2615
pubmed: 27538407
Lancet. 2016 Oct 22;388(10055):2039-2052
pubmed: 27112094
Am J Nephrol. 2006;26(4):363-71
pubmed: 16873992
Am J Kidney Dis. 2000 Feb;35(2):313-8
pubmed: 10676733
Genes Dev. 2002 Dec 15;16(24):3223-35
pubmed: 12502743
Cell Metab. 2007 Feb;5(2):115-28
pubmed: 17276354
Sci Rep. 2017 Oct 25;7(1):14004
pubmed: 29070821
FEBS Lett. 2018 Jun;592(12):2126-2139
pubmed: 29749013

Auteurs

Takeo Ishii (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Department of Medicine, Yokohama Daiichi Hospital, Kanagawa, Japan.

Tomohiro Kumagae (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Department of General Internal Medicine, Shonan Kamakura General Hospital, Kanagawa, Japan.

Hiromichi Wakui (H)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Shingo Urate (S)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Shohei Tanaka (S)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Eriko Abe (E)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Toru Suzuki (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Takahiro Yamaji (T)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Sho Kinguchi (S)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Ryu Kobayashi (R)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Kotaro Haruhara (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Takashi Nakamura (T)

Medical Affairs Department, Sanwa Kagaku Kenkusho., Co., Ltd, Aichi, Japan.

Shuzo Kobayashi (S)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Department of General Internal Medicine, Shonan Kamakura General Hospital, Kanagawa, Japan.

Kouichi Tamura (K)

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH